Authors


Katlyn Nemani, BA

Latest:

HIT Press Club AJMC - Katlyn Nemani, BA

Katlyn Nemani, BA, Tufts University School of Medicine, discusses her paper


Pamela N. Roberto, MPP

Latest:

Binary Measures for Associating Medication Adherence and Healthcare Spending

The use of an 80% threshold or other binary cut point may be insufficient for characterizing the relationship between medication adherence and Medicare spending.


Tina Huynh, MPH, MHA

Latest:

VA Geriatric Scholars Program’s Impact on Prescribing Potentially Inappropriate Medications

Primary care teams reduced their prescribing of potentially inappropriate medications to older veterans after participation in the Veterans Affairs (VA) Geriatric Scholars Program.


Angelo Elmi, PhD

Latest:

Previously Unrecognized Trends in Diabetes Consumption Clusters in Medicare

Medicare beneficiaries with diabetes who are at the lowest levels of healthcare consumption often become some of the highest level consumers in subsequent years.


Sharon Reif, PhD

Latest:

How Health Plans Promote Health IT to Improve Behavioral Health Care

Commercial health plans promote the use of health IT to support behavioral health care access and delivery.



Cameron B. Haas, MPH

Latest:

Time to Fecal Immunochemical Test Completion for Colorectal Cancer

Targeted interventions by patient characteristics to improve fecal immunochemical test completion could reduce disparities in colorectal cancer screening and improve overall compliance with screening recommendations.




Nora Mueller, MAA

Latest:

How Do Providers Prioritize Prevention? A Qualitative Study

Primary care providers utilize many strategies for prioritizing preventive care during time-constrained clinical encounters, in addition to being prompted by clinical reminders.








Henry N. Young, PhD

Latest:

Innovation, Affordability, Access: Alzheimer Disease Drugs and the Inflation Reduction Act

The authors explore the economic impact and accessibility challenges of new Alzheimer disease drugs under the Inflation Reduction Act, with emphasis on Medicare, pricing, and health care equity.


Joel E. Segel, PhD

Latest:

No Free Lunch: The Misaligned Incentives of the American Health Care System

The author highlights reasons why we have not seen substantial cost savings in the health care industry and why future efforts are likely to continue to see forceful pushback, as well as offers potential solutions.



Markus Wieser, MD

Latest:

Frequency of and Harm Associated With Primary Care Safety Incidents

Physicians' and nurses' assessments of the frequency and harm of incidents can be a supplemental method to study patient safety in the primary care office.


Maria G. Montez, RN, MSHP

Latest:

Effectiveness and Cost-Effectiveness of Diabetes Prevention Among Adherent Participants

Over 10 years, among adherent participants, lifestyle intervention and metformin were effective and cost-effective for diabetes prevention compared with placebo.



Norman LaFrance, MD

Latest:

Cost of Care for Malignant and Benign Renal Masses

Methods for better identifying malignant versus benign disease before nephrectomy could provide significant benefits to patients and payers.



Mark E. Lewis, MPH

Latest:

ACO Use of Case Mix Index to Comprehensively Evaluate Postacute Care Partners

This article describes how one accountable care organization (ACO) created a risk-adjusted algorithm to evaluate current and potential candidates for skilled nursing facility partnerships.


Michael A. Rodriguez, MD, MPH

Latest:

Cervical Cancer Screening Overuse and Underuse: Patient and Physician Factors

Cervical cancer screening underuse and overuse occur commonly in clinical practice and identifiable patient and physician factors can be targeted for quality improvement.



Qianyi Li, MS

Latest:

Cost-effectiveness of Intensification With SGLT2 Inhibitors for Type 2 Diabetes

Adding a sodium-glucose co-transporter 2 (SGLT2) inhibitor dominated switching to a glucagon-like peptide 1 receptor agonist over the lifetimes of patients with type 2 diabetes not at glycated hemoglobin A1c target after treatment with metformin plus a dipeptidyl peptidase-4 inhibitor.



AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo